Safety Assessment of Alkyl PEG Sulfosuccinates as Used in Cosmetics

2015 ◽  
Vol 34 (2_suppl) ◽  
pp. 70S-83S
Author(s):  
Wilbur Johnson ◽  
Bart Heldreth ◽  
Wilma F. Bergfeld ◽  
Donald V. Belsito ◽  
Ronald A. Hill ◽  
...  

The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) reviewed the safety of alkyl polyethylene glycol (PEG) sulfosuccinates, which function in cosmetics mostly as surfactants/cleansing agents. Although these ingredients may cause ocular and skin irritation, dermal penetration is unlikely because of the substantial polarity and molecular size of these ingredients. The Panel considered the negative oral carcinogenicity and reproductive and developmental toxicity data on chemically related laureths (PEG lauryl ethers) and negative repeated dose toxicity and skin sensitization data on disodium laureth sulfosuccinate supported the safety of these alkyl PEG sulfosuccinates in cosmetic products, but. The CIR Expert Panel concluded that the alkyl PEG sulfosuccinates are safe in the present practices of use and concentration when formulated to be nonirritating.

2016 ◽  
Vol 35 (3_suppl) ◽  
pp. 47S-53S ◽  
Author(s):  
Wilbur Johnson ◽  
Bart Heldreth ◽  
Wilma F. Bergfeld ◽  
Donald V. Belsito ◽  
Ronald A. Hill ◽  
...  

Polyquaternium-22 and polyquaternium-39 are polymers that function as antistatic agents, film formers, and hair fixatives in cosmetic products. These ingredients are being used at concentrations up to 2% (polyquaternium-22, in a rinse-off product) and up to 3% (polyquaternium-39, in rinse-off and leave-on products). The unreacted monomer content of these ingredients was considered low and of no toxicological concern. Limited data showed no skin irritation/sensitization. Although these ingredients were nongenotoxic in bacterial assays, mammalian genotoxicity, carcinogenicity, and reproductive and developmental toxicity data were not available. These polymers, however, are large, highly polar molecules that would likely not be absorbed, and neither local effects in the respiratory tract nor systemic toxicity are expected following product application/exposure. The Expert Panel concluded that polyquaternium-22 and polyquaternium-39 are safe in the present practices of use and concentration in cosmetic formulations.


2018 ◽  
Vol 37 (2_suppl) ◽  
pp. 5S-9S
Author(s):  
Wilbur Johnson ◽  
Wilma F. Bergfeld ◽  
Donald V. Belsito ◽  
Ronald A. Hill ◽  
Curtis D. Klaassen ◽  
...  

The Cosmetic Ingredient Review Expert Panel (Panel) reviewed the safety of polyethylene glycol (PEG)-150 pentaerythrityl tetrastearate, which functions as a viscosity-increasing agent-aqueous in cosmetic products and is being used at concentrations up to 5%. Given the chemical structure (large molecule), skin penetration is not likely. The available toxicity data and the low ingredient use concentrations suggest that systemic toxicity would not be likely even if percutaneous absorption were to occur. Additionally, the negative human repeated insult patch test data on the undiluted ingredient were deemed sufficient for evaluating skin irritation and sensitization potential. The Panel concluded that PEG-150 pentaerythrityl tetrastearate is safe in cosmetics in the present practices of use and concentration described in this safety assessment.


2018 ◽  
Vol 37 (3_suppl) ◽  
pp. 80S-89S ◽  
Author(s):  
Wilbur Johnson ◽  
Wilma F. Bergfeld ◽  
Donald V. Belsito ◽  
Ronald A. Hill ◽  
Curtis D. Klaassen ◽  
...  

Pentaerythrityl tetra-di -t-butyl hydroxyhydrocinnamate functions as an antioxidant in cosmetic products and is used at concentrations up to 0.8%. Given the high molecular weight of this ingredient, skin penetration is not likely. The available toxicity data, together with the low ingredient use concentrations, suggest that systemic toxicity would not be likely if percutaneous absorption were to occur. Additionally, the negative human repeated insult patch test data at a concentration of 0.5% were deemed sufficient for evaluating the skin irritation and sensitization potential of pentaerythrityl tetra-di -t-butyl hydroxyhydrocinnamate over the range of use concentrations in cosmetic products. The Cosmetic Ingredient Review Expert Panel concluded that pentaerythrityl tetra-di -t-butyl hydroxyhydrocinnamate is safe in cosmetics in the present practices of use and concentration described in this safety assessment.


2008 ◽  
Vol 27 (1_suppl) ◽  
pp. 55-62 ◽  

Cocamidopropylamine Oxide is a tertiary amine oxide which functions as a hair-conditioning agent and as a surfactant, currently used in 60 cosmetic formulations at concentrations between 0.07% and 4.0%. In an earlier safety assessment, the Cosmetic Ingredient Review (CIR) Expert Panel had determined that the available data were insufficient to support the safety of this ingredient in cosmetic products. Additional data have now been provided and reviewed. Cocamidopropylamine Oxide was determined to have an acute oral LD50 between 500 and 1000 mg/kg day-1 using rats. The acute dermal LD50 in rats was >2174 mg/kg day-1 . A 28-day repeated oral dose toxicity study in rats found hemolytic anemia at 150 and 1000 mg/kg day-1, with a no observed effect level (NOEL) of 15 mg/kg day-1 . At 5%, Cocamidopropylamine Oxide solution was not a primary dermal irritant. Application of 81.5% Cocamidopropylamine Oxide to rabbit skin caused moderate irritation under Draize classification scale, but 81.5% Cocamidopropylamine Oxide in rabbit eyes caused severe irritation. A maximization study classified Cocamidopropylamine Oxide as a nonsensitizer to guinea pig skin. Cocamidopropylamine Oxide was not mutagenic in an Ames test, with and without metabolic activation. No evidence of increased chromosomal aberrations were noted in human lymphocytes treated with 81.5% Cocamidopropylamine Oxide. In a clinical study, 7.5% Cocamidopropylamine Oxide was not a sensitizer, although it did produce some reactions typical of mild irritation. Although the impurities, amidoamine and dimethylaminopropylamine, have been implicated in contact allergy reactions to products containing cocamidopropylamine betaine, clinical testing of a product with cocamidopropylamine betaine containing these impurities, at levels comparable to those found in Cocamidopropylamine Oxide, failed to produce a reaction in 10 individuals known to be sensitive to cocamidopropylamine betaine. Two repeat-insult patch tests using a facial wash with 1% raw material containing 35% to 36.5% Cocamidopropylamine Oxide did not find evidence of dermal sensitization. Tests for dermal phototoxicity and photoallergenicity with the same facial wash product also did not produce evidence of effect. The CIR Expert Panel recognizes that there are data gaps regarding the use and concentration of this ingredient. However, the overall information available on types of products in which this ingredient is used and at what concentration indicate a pattern of use, which was considered by the Expert Panel in assessing safety. Overall, these data demonstrate that Cocamidopropylamine Oxide has low toxicity in animal and in vitro tests. Although there are no available carcinogenicity data, the available genotoxicity data, combined with the absence of any structural alerts, suggest no carcinogenic potential. The Panel noted the absence of reproductive and developmental toxicity data. Because this ingredient has a highly polarized molecular structure, the Panel considered that it would be, at most, slowly absorbed. Given that most of the uses and the highest use concentration of 4% is found in rinse-off products, the Panel determined that the available data suggest that Cocamidopropylamine Oxide is safe as used in rinse-off products. Although dermal penetration may be slow, data on the extent of dermal penetration of Cocamidopropylamine Oxide are needed to support the safety of leave-on uses. If there is significant dermal absorption, dermal reproductive and developmental toxicity data may be needed.


2007 ◽  
Vol 26 (3_suppl) ◽  
pp. 79-88 ◽  

Hexamidine Diisethionate functions as a biocide in cosmetics at concentrations of 0.03% to 0.1% in 38 cosmetic products. Hexamidine functions as a biocide and preservative in cosmetics, but is not in current use in cosmetics, but it is used in over-the-counter (OTC) drug products. Hexamidine was poorly absorbed by human cadaver skin when in water-oil formulations or in a gel that simulated a cosmetic product formulation. Hexamidine Diisethionate was poorly absorbed by the skin of live rats and was not stored in any tissue type. Hexamidine Diisethionate given to rats intravenously was rapidly metabolized to Hexamidine. Excretion was primarily via the feces, with a small amount excreted in the urine. Acute oral LD50 values of Hexamidine Diisethionate were 0.71 to 2.5 g/kg in mice and 0.75 g/kg in rats. Dermal exposure to 4 g/kg Hexamidine Diisethionate in rats or up to 9.4 ml/kg of a 0.1% Hexamidine Diisethionate solution under occlusion in rabbits produced no mortality or other signs of toxicity. The no-observed-effect level (NOEL) for oral subchronic toxicity of Hexamidine Diisethionate in rats was 50 mg/kg/day. No signs of toxicity were observed with 2% Hexamidine Diisethionate in subchronic studies using rabbits. Application of 0.1 ml of 0.11% Hexamidine Diisethionate in aqueous solution to the eyes of rabbits produced transient reactions; 0.05% produced no reactions. Slight erythema was observed with 0.10% Hexamidine Diisethionate applied to the abraded skin of 1/11 albino rabbits. A 40% solution of Hexamidine Diisethionate applied to 10% of the body surface of rats produced slight erythema, slight edema, and scabbing in some animals at varying times after treatment. Hexamidine Diisethionate was not a sensitizer in the guinea pig maximization test or in an intracutaneous guinea pig sensitization test. Hexamidine Diisethionate was not a photosensitizer in albino rabbits. Hexamidine Diisethionate was not mutagenic in a bacterial reverse mutagenicity assay or clastogenic in mammalian cells. Hexamidine Diisethionate at 0.10% did not provoke primary irritation, inflammation, or sensitization in a clinical test of 200 human subjects. One case report of photosensitivity to Hexamidine and one of contact sensitivity to Hexamidine were reported. There were nine case reports of contact sensitivity to Hexamidine Diisethionate. A European safety assessment recommended a limit of 0.1% Hexamidine Diisethionate in leave-on and rinse-off cosmetic products. In considering the available data, the Cosmetic Ingredient Review (CIR) Expert Panel acknowledged the lack of carcinogenicity and reproductive/developmental toxicity data. Because genotoxicity studies were negative, and there were no structural alerts, the Panel concluded that it was unlikely that these ingredientswould be carcinogenic. Because the rate of absorption of Hexamidine and Hexamidine Diisethionate is slow, there is no tissue accumulation, and excretion is rapid and complete, and there was no toxicity in a subchronic study, the Panel concluded that dermal exposures would not likely present a risk of reproductive/ developmental toxicity. The Panel noted that a guinea pig maximization study using Hexamidine Diisethionate produced no dermal reactions and that a clinical test at 0.1% produced no irritation or sensitization. The Panel also expressed concern regarding the possible presence of 1,4-dioxane as an impurity, and stressed that the cosmetic industry should continue to use the necessary purification procedures to remove these impurities from the ingredient before blending into cosmetic formulations. The Panel noted that there are no data for concentration of use for eye makeup and baby products, and was concerned that there should not be unrestricted concentration levels in these product categories. Although there are gaps in knowledge about product use, the overall information available on the types of products in which these ingredients are used and at what concentration indicate a pattern of use. Within this overall pattern of use, the Expert Panel considers all ingredients in this group to be safe at concentrations up to and including 0.1%.


1996 ◽  
Vol 15 (2) ◽  
pp. 166-176 ◽  

The polymer Polyvinyl Acetate (PVAc) is used in cosmetics as a binder, emulsion stabilizer, and hair fixative. Current reported uses are limited to a few eye makeup formulations. As used in cosmetic formulations, PVAc is an emulsion containing 55 to 60% resin. The Cosmetic Ingredient Review (CIR) Expert Panel had previously published a review of the safety of this ingredient in J Am Coll Toxicol (1992;11:465–74) concluding that the available data were not sufficient to support safety. The report included mutagenesis and carcinogenesis studies with negative findings. Data from pregnant rabbits indicated that PVAc was not transferred to the fetus, even when administered by the i.v. route, suggesting that present cosmetic use practices preclude any reproduction or developmental toxicity hazard to humans. Composition and impurities data and human skin irritation and sensitization data, however, were not available. Data received since that assessment include the nature of the ingredient as used in cosmetics, the identity of many of the impurities, and the test results of human exposure to aqueous emulsions containing 50% PVAc. Less than 2 ppm of arsenic and <20 ppm of heavy metals reportedly will be in a typical emulsion. The clinical testing of an aqueous emulsion with 50% PVAc produced no irritation or sensitization. Based on the recent information, this ingredient is found to be safe for use as a cosmetic ingredient in the present practices of use.


2012 ◽  
Vol 31 (5_suppl) ◽  
pp. 147S-168S ◽  
Author(s):  
Wilbur Johnson ◽  
Wilma F. Bergfeld ◽  
Donald V. Belsito ◽  
Ronald A. Hill ◽  
Curtis D. Klaassen ◽  
...  

Caprylyl glycol and related 1,2-glycols are used mostly as skin and hair conditioning agents and viscosity agents in cosmetic products, and caprylyl glycol and pentylene glycol also function as cosmetic preservatives. The Cosmetic Ingredient Review (CIR) Expert Panel noted that, while these ingredients are dermally absorbed, modeling data predicted decreased skin penetration of longer chain 1,2-glycols. Because the negative oral toxicity data on shorter chain 1,2-glycols and genotoxicity data support the safety of the 1,2-glycols reviewed in this safety assessment, the Panel concluded that these ingredients are safe in the present practices of use and concentration described in this safety assessment.


1999 ◽  
Vol 18 (1_suppl) ◽  
pp. 1-10

Hydroxystearic Acid is a fatty acid used as a surfactant–cleansing agent in cosmetic products. Initial review of available safety test data resulted in a finding that there were insufficient data to support the safety of Hydroxystearic Acid for use in cosmetic products. Data needed included concentration of use, chemical characterization, dermal reproductive and developmental toxicity, genotoxicity (and carcinogenicity data if the genotoxicity data were positive), and shin irritation data. Subsequent to that conclusion, new data were received. Use concentrations were reported as high as 10%. Small amounts of other fatty acids are commonly found in preparations of Hydroxystearic Acid. Genotoxicity was not found in bacterial or mammalian systems and only subcutaneous sarcomas at the site of injection were found in carcinogenicity studies. Dermal reproductive and developmental toxicity studies were negative. Skin irritation was produced by antiperspirant prototype formulations containing Hydroxystearic Acid under occluded or semioccluded patch test conditions. It was considered that such formulations under those exaggerated conditions can be irritating, but are generally not irritating in actual use. Because Hydroxystearic Acid and Stearic Acid are structurally similar, data from a previous safety assessment of Oleic Acid, Lauric Acid, Palmitic Acid, Myristic Acid, and Stearic Acid were summarized. On the basis of the animal and clinical data, it was concluded that Hydroxystearic Acid is safe as a cosmetic ingredient in the present practices of use.


1985 ◽  
Vol 4 (5) ◽  
pp. 31-63 ◽  

p-Hydroxyanisole is used as an antioxidant in cosmetic products at concentrations of up to 1.0 percent. The acute oral LD50 of p-Hydroxyanisole in rats was estimated as 1630 mg/kg. Undiluted p-Hydroxyanisole is a severe skin and ocular irritant in rabbits but produced minimal eye irritation at 0.1 percent and minimal rabbit skin irritation at 5 percent. Skin sensitization to p-Hydroxyanisole occurred when guinea pigs were treated at 0.5 M. p-Hydroxyanisole is a skin-depigmenting agent at concentrations approximating those used in cosmetic products. p-Hydroxyanisole was nonmutagenic in the Ames assay. No local toxic changes or tumors were observed following long-term application of 5 and 10 percent p-Hydroxyanisole. The antioxidant was inactive as a tumor promoter. Solutions of p-Hydroxyanisole produced embryotoxicity but not teratogenicity. The function of p-Hydroxyanisole in cosmetics is that of an antioxidant; it is not intended for use as a skin lightener or skin-depigmenting agent. Because of the depigmenting action of p-Hydroxyanisole in black guinea pigs at reported concentrations approaching those used in cosmetics, it is concluded that p-Hydroxyanisole is unsafe for use as a cosmetic ingredient.


2021 ◽  
Vol 40 (1_suppl) ◽  
pp. 20S-33S
Author(s):  
Christina L. Burnett ◽  
Wilma F. Bergfeld ◽  
Donald V. Belsito ◽  
Curtis D. Klaassen ◽  
Daniel C. Liebler ◽  
...  

The Expert Panel for Cosmetic Ingredient Safety (Panel) reassessed the safety of the mixture Methylchloroisothiazolinone (MCI)/Methylisothiazolinone (MI), which functions as a preservative in cosmetic products. The Panel reviewed relevant animal and human data provided in this safety assessment, and data from the previously published safety assessment of this mixture, and concluded that MCI/MI is safe in cosmetics when formulated to be nonsensitizing, based on the results of a quantitative risk assessment or similar methodology; however, at no point should concentrations exceed 7.5 ppm in leave-on products or 15 ppm in rinse-off products.


Sign in / Sign up

Export Citation Format

Share Document